BioceltixS.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-08-13
Share capital
553 225,30 PLN
Activity description

Bioceltix is a Polish biotechnology company that develops innovative veterinary biological drugs, specifically using allogenic stem cells to treat conditions such as osteoarthritis in dogs and atopic dermatitis in both dogs and horses. The company focuses on immunomodulatory therapies targeting inflammatory and autoimmune diseases, adhering to high pharmaceutical quality standards. Bioceltix is also advancing a research project for a cell-free biological drug aimed at treating atopic dermatitis in dogs.

Registered address
ul. Bierutowska 57-59/Bud.iii, 51-317 Wrocław, Poland
Website
bioceltix.comWebsite active
Email
Email address current
Phone
Social media
Electronic delivery address
AE:PL-21907-79452-GJCCI-09

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Stock quotes

PLN 69.20
-0.40 (-0.57%)
69.0069.5069.2010:0012:0014:0016:00
Open
PLN 69.00
High
PLN 69.80
Low
PLN 68.90
Volume
3.41K
Avg. vol.
6.16K
Market cap
PLN 382.83M
P/E ratio
–
EPS
-PLN 3.35
Shares outstanding
5.53M
52-week
PLN 68.80 – 76.00
Dividend yield
–
Dividend
–
Ex dividend date
–
ISIN
PLBCLTX00019
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD -17.56kUSD -1.36mUSD -1.37m
Q1 2026USD 1.89kUSD -1.56mUSD -1.53m
Q4 2025USD 0.00USD -857.86kUSD -850.33k
Q3 2025USD 0.00USD -1.12mUSD -1.10m

Results for Q3 2026:Nov 27, 2026

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 616.32kMedianUSD 133.91kAverageUSD 4.65m
Net profit
This companyUSD -3.81mMedianUSD -54.78AverageUSD 310.10k
Operating costs
This companyUSD 4.35mMedianUSD 175.72kAverageUSD 4.46m
Assets
This companyUSD 18.99mMedianUSD 254.44kAverageUSD 8.12m

News

32/2026 Conclusion of a significant contract for the execution of steel structures as part of the construction of a new pharmaceutical plant

1/2026 Information on the status of Good Practices implementation

31/2026 Assessment by the Management Board of the Issuer of the list of questions received from the European Medicines Agency and schedule of further work in the registration process of product BCX-CM

30/2026 Registration of statute changes

29/2026 Receipt of certificate of finality of building permit decision for the investment entitled “Biological veterinary medicines plant”

Industry

Bank accounts

Registered as a VAT taxpayer on 2016-08-30. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication dateEvent
Jun 1, 2021Shareholders' meeting convened
Dec 29, 2020Shareholders' meeting convened
Jul 8, 2020Shareholders' meeting convened

Public aid

15 public aid cases recorded, with a total value of $17,294,925.

PurposeGross amount
Aid for research and development projects: industrial research
$1.4M
Aid for research and development projects: experimental development
$479.1K
Regional investment aid
$4.4M

European Funds

5 projects co-financed from European Funds recorded, with total EU co-financing of $12,633,260.

ProjectEU co-financing
Innowacyjny bezkomórkowy lek biologiczny dla zastosowań w weterynarii (InnoBioVet)
$3.8M
Budowa i uruchomienie wytwórni farmaceutycznej innowacyjnych weterynaryjnych produktów leczniczych terapii zaawansowanej
$4.3M
Opracowanie biologicznego weterynaryjnego produktu leczniczego BCX-CM-AD przeznaczonego do leczenia atopowego zapalenia skóry u psów
$2.5M

Tenders

No recorded participation in tenders.

Authorized Representatives

Andrij Włach – Attorney-in-fact (joint)
Łukasz Piotr Bzdzion – President of the Management Board
Grzegorz Ostropolski – Attorney-in-fact (joint)
Paweł Wielgus – Management Board Member

Manner of representation

In the case of a one-person management board, the President of the Management Board is authorized to make declarations and sign on behalf of the company independently. In the case of a multi-member management board, joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy, is required to make declarations and sign on behalf of the company.

Supervisory board

Wojciech Aksman – Supervisory Board Member
Beata Bożena Porowska – Supervisory Board Member
Ewelina Pawlus Czerniejewska – Supervisory Board Member
Ewa Więcławik – Supervisory Board Member
Michał Jank – Supervisory Board Member

Beneficial owners

Person

Competitors

Name
FamicordtxS.A.
Ecoverseasp. z o.o.
OrthogetS.A.
CTI Clinical Trial And Consulting Services Polandsp. z o.o.
VET Cell Techsp. z o.o.
BiottsS.A.
PolbionicaS.A.
Green ZebrasS.A.
BiocamS.A.
Medicofarma BiotechS.A.

Change history

DateEvent
2025-11-06Share capital change
2025-08-26PKD change
2024-06-27Share capital change
2023-07-03Share capital change
2023-04-28Share capital change

FAQ

Last updated: 2026-10-07